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Common polygenic variation in coeliac disease and
conﬁrmation of ZNF335 and NIFA as disease
susceptibility loci
Ciara Coleman1,10, Emma M Quinn1,10, Anthony W Ryan1, Judith Conroy2, Valerie Trimble1, Nasir Mahmud1,
Nicholas Kennedy1, Aiden P Corvin3, Derek W Morris4, Gary Donohoe4, Colm O’Morain5, Padraic MacMathuna6,
Valerie Byrnes7, Clifford Kiat7, Gosia Trynka8, Cisca Wijmenga9, Dermot Kelleher1,11, Sean Ennis2,
Richard JL Anney3 and Ross McManus*,1
Coeliac disease (CD) is a chronic immune-mediated disease triggered by the ingestion of gluten. It has an estimated prevalence
of approximately 1% in European populations. Speciﬁc HLA-DQA1 and HLA-DQB1 alleles are established coeliac susceptibility
genes and are required for the presentation of gliadin to the immune system resulting in damage to the intestinal mucosa. In the
largest association analysis of CD to date, 39 non-HLA risk loci were identiﬁed, 13 of which were new, in a sample of 12 014
individuals with CD and 12 228 controls using the Immunochip genotyping platform. Including the HLA, this brings the total
number of known CD loci to 40. We have replicated this study in an independent Irish CD case–control population of 425 CD
and 453 controls using the Immunochip platform. Using a binomial sign test, we show that the direction of the effects of
previously described risk alleles were highly correlated with those reported in the Irish population, (P=2.2 ×10−16). Using the
Polygene Risk Score (PRS) approach, we estimated that up to 35% of the genetic variance could be explained by loci present
on the Immunochip (P=9×10−75). When this is limited to non-HLA loci, we explain a maximum of 4.5% of the genetic
variance (P=3.6×10−18). Finally, we performed a meta-analysis of our data with the previous reports, identifying two further
loci harbouring the ZNF335 and NIFA genes which now exceed genome-wide signiﬁcance, taking the total number of CD
susceptibility loci to 42.
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INTRODUCTION
Coeliac disease (CD) is a complex and chronic immune-mediated
disease affecting the small intestine with a prevalence of approximately
1% in the European population.1,2 Coeliac patients are sensitive to the
ingestion of gliadin and related proteins, which initiate an immune
response ultimately leading to villous atrophy and ﬂattening of the
intestinal mucosa. CD is a polygenic disorder with probandwise
concordance rates in monozygotic twins of over 80% compared with
17% in dizygotic twins leading to estimates of heritability in excess of
80%.3,4 The HLA locus is the most important inherited susceptibility
factor, variously estimated to account for up to 40% of the genetic
variance.5–8 The vast majority of CD patients carry either HLA-DQ2
or DQ8 heterodimers, which are expressed on antigen-presenting cells
and present gliadin to T cells. However, environmental and non-HLA
loci also contribute to susceptibility because CD-associated HLA-DQ
molecules are not alone sufﬁcient to cause CD susceptibility, which is
evident from the fact that they are common in the general population
(usually reported as 30% or greater), whereas only a small proportion
of carriers will ever develop CD.9
A number of genome-wide association studies (GWAS) have been
carried out to identify additional CD susceptibility loci. The ﬁrst study
was performed in a UK sample of 778 patients and 1422 controls10 and
led to the unequivocal identiﬁcation of the ﬁrst non-HLA risk locus in
CD, the IL2/IL21 region of chromosome 4 (odds ratio (OR)= 0.63, CI
(0.57–0.71)). A subsequent GWAS in a larger multinational sample
brought the number of established non-HLA risk loci to 26.11,12 Early
GWAS arrays, however, failed to adequately capture much of the
genetic variation of disease-associated loci, making it difﬁcult to
identify the location of the true risk variant. Furthermore, the lack of
uniformity in marker selection between different arrays made compar-
isons with other diseases difﬁcult. Consequently, the Immunochip was
developed, a low cost Illumina Inﬁnium genotyping array containing
196 524 common and rare polymorphisms at loci implicated in GWAS
of 12 major autoimmune and inﬂammatory diseases including CD.13
The dense, targeted, genotyping afforded by this array was designed to
allow improved signal localisation and cross disease comparison.
Trynka and colleagues,14 using the Immunochip in a study of 12
014 CD patients and 12 228 controls from seven geographic regions,
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reported 57 independent CD association signals across 39 non-HLA
loci. These consisted of loci meeting genome-wide signiﬁcance (GWS;
Po5× 10− 8) in their data and/or in previous CD GWAS and
replication data sets. Notably, this included 13 loci not previously
associated with CD, bringing the total number of CD risk loci to 40
including the HLA. Similar to other complex diseases, the individual
effect size for most of these observed non-HLA variants is small (OR
1.12–1.36) and together they explain only a small proportion of
disease risk.
It has been shown that by combining the loci of small effect,
including those that do not achieve GWS, it is possible to explain a
greater proportion of the variance in complex traits. One approach to
capturing this genetic liability is the polygenic risk score (PRS)
described by Purcell and colleagues.15 The PRS combines the effects
of multiple common variants and has been successfully used to
examine the inﬂuence of risk alleles en masse to disease susceptibility
in a range of complex disorders such as psychiatric illness,16 multiple
sclerosis17 and cardiovascular disease.18 In essence, the PRS is a risk
score for an individual calculated from the cumulative burden of risk
alleles carried by that individual; these risk alleles are then weighted
according to their observed effect size on disease (OR) to come up
with the ﬁnal PRS. In CD, similar approaches to PRS have been
applied by Romanos and colleagues,19 who developed a CD genetic
risk model by combining HLA plus the 57 non-HLA SNP associated
loci, and Abraham and colleagues,20 who developed genomic risk
scores for CD based on approximately 250 SNPs.
In this analysis, we ﬁrst set out to perform an association study using
the Immunochip array in an independent Irish population of 425 CD
and 453 controls and to present these new data in the context of
previously identiﬁed association signals. Secondly, we performed meta-
analyses of these new data combined with those reported by Trynka and
colleagues14 to test whether this led to the discovery of any additional
GWS loci. Thirdly, in order to examine the polygenic contribution
across studies, we derived PRSs for HLA and non-HLA CD loci
identiﬁed and weighted according to the ﬁndings from the Trynka
et al14 association study (discovery set) and calculated the proportion of
variance explained for the Irish study (estimated via Nagelkerke’s
pseudo R2). Finally, we investigated the discriminatory capacity of the
PRS derived from our study to distinguish case status in this sample.
MATERIALS AND METHODS
Sample description
All individuals are Caucasian and have self-reported Irish ancestry as deﬁned by
four grandparents of exclusively Irish origin. Genomic DNA was extracted from
peripheral blood samples. CD were assigned on the basis of positive serology to
antibody-based tests (anti-tTG and anti-EMA) followed by examination of the
histological appearance of small intestinal biopsy samples and noting clinical
response to a gluten-free diet. Controls were an anonymous unselected (ie not
screened for CD) healthy sample of blood donors from the general population
provided by the TCD/IMM population DNA biobank. Written and informed
consent was obtained from all subjects, and the study was approved by the
Research Ethics Committees of St James’s Hospital Dublin and all other
contributing centers.
Genotyping and genotyping quality control
Genotyping was performed by using the Illumina Inﬁnium High-Density array
(Illumina Inc., San Diego, CA, USA) at the UCD Academic Centre on Rare
Diseases (ACoRD). Genotypes were called using the Illumina GenomeStudio
software using the cluster set of 172 242 autosome/x-chromosome variants
from the Trynka et al14 study (Immuno_BeadChip_11419691_B.bpm, NCBI
build 36 (hg18)).
All quality control of the genotype data was performed using PLINK v1.07.21
Additional calculations and visualisations were performed in STATA v13 using
self-authored scripts. Individual genotyping samples were excluded based on
per-sample call rate (missing 45%), excessive autosomal heterozygosity
(43SD from sample mean) and evidence of relatedness (up to and including
second degree relatives). The population was restricted to a proxy-North
Western European ancestry subset as deﬁned by similarity to the HAPMAP
CEPH reference dataset. Population outliers were identiﬁed by multi-
dimensional scaling and individuals 43SD from the CEPH mean component
score for the ﬁrst two principal components were removed. Individual SNPs
were removed from the association analysis for low call rate (o95%) deviation
from Hardy–Weinberg equilibrium in controls (Po1× 10− 5), or low minor
allele frequency (o0.01). Following quality control, 425 CD cases and 453
controls genotyped across 143 074 markers were available for analysis.
Genetic association
Association analysis was performed in PLINK v1.0721 using logistic regression
adjusting for gender and 10 population covariates (principal components
generated from the multi-dimensional scaling routine in PLINK). Raw
genotype intensity plots for all markers described in Table 1 were visually
inspected to conﬁrm cluster separation and genotyping quality. These data have
been made publically available at the GWAS Central database22 at the URL
(http://www.gwascentral.org/study/HGVST1830).
Meta-analysis
Meta-analyses of the ﬁndings from our data and those of Trynka et al14 were
performed using METAL.23 Prior to analysis, SNPs were corrected for strand
inconsistencies; any SNPs where strand ambiguity was possible (A/T or C/G)
were excluded from analysis. Allele frequencies were compared between the
Irish and UK controls from the Trynka et al14 dataset and were found to be
Table 1 Eleven of the 57 independent previously reported coeliac disease signals were nominally signiﬁcant in the Irish sample
Chromosome Variant ID Allele MAFIRISH ORIrish PIrish ORTrynka PTrynka Nearest gene
4 rs13132308:g.123770564A4G G 0.1686 0.614 7.45E-04 0.7054 1.87E-38 ADAD1, IL2, IL21, KIAA1109
18 rs11875687:g.12833137T4C C 0.1899 1.527 1.87E-03 1.173 1.92E-10 PTPN2
3 rs76830965:g.161120372C4A A 0.1595 1.547 3.06E-03 1.36 2.56E-27 SCHIP1, IL12A
12 rs3184504:g.110368991T4C T 0.4914 1.391 3.41E-03 1.192 5.42E-21 ATXN2, SH2B3
11 rs61907765:g.127897147C4T T 0.2175 1.459 3.69E-03 1.175 3.43E-13 ETS1
6 rs1107943:g.159418255T4C C 0.07062 1.819 6.31E-03 1.221 7.95E-09 TAGAP
8 rs10808568:g.129333242A4C C 0.2472 0.7258 1.03E-02 0.9132 2.20E-05 PVT1
11 rs10892258:g.118085075G4A A 0.2275 0.7165 1.11E-02 0.8611 1.73E-11 DDX6, TREH
1 rs72657048:g.25162321C4G C 0.4525 0.777 2.26E-02 0.918 3.79E-06 RUNX3
4 rs62323881:g.123257745A4G A 0.07973 1.568 2.98E-02 1.204 6.87E-08 ADAD1, IL2, IL21, KIAA1109
1 rs1359062:g.190808095C4G C 0.1775 0.7605 5.00E-02 0.7691 2.55E-25 RGS1
All genomic locations are based on human genome build 18.
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highly concordant (r2= 0.996). Studies were combined using an inverse
variance weighted approach combining the association signal (P-values). We
also calculated I2 as a measure of heterogeneity.
Sign test
To examine whether the observed direction of effect in our sample was
concordant with markers previously identiﬁed as GWS by Trynka et al,14 a
binomial sign-test was performed. To limit the effect of linkage disequilibrium
on these data, linkage-independent SNPs were identiﬁed in the discovery set by
applying the –clump ﬂag in PLINK. Brieﬂy, sequentially from the most
associated marker (Po5× 10− 8), all additional SNPs within a 1Mb window
that were correlated with it at an r240.2 were excluded. This left us with 280
LD-independent GWS SNPs in total.
PRS analyses
Using the Trynka et al14 association study as the discovery set, polygene scores
were calculated for the Irish study individuals using the –score ﬂag in PLINK
v1.07. In total, we calculated eight PRS limited to SNPs that met an association
threshold in the discovery analyses. These thresholds were Po5× 10− 8,
Po0.01, Po0.05, Po0.1, Po0.2, Po0.3, Po0.4 and Po0.5. All analyses
were calculated on the putative risk allele and a relative weight was applied to
each allele as the log OR of the association signal observed in the discovery
analyses. Individual PRS were then calculated as the sum of all risk variants
carried by that individual weighted for the effect size. To limit the effect of
linkage disequilibrium on these data, linkage-independent SNPs were identiﬁed
in the discovery set as described above.
To examine the predictive strength of the derived PRS in our sample, a
nested logistic regression was performed. All scores were converted to a scale of
0–1 and individual SNP missingness was corrected by mean imputation from
available SNPs genotyped in the individual. Two nested logistic regression
models were applied; (i) case status predicted by score, gender and population
covariates and (ii) case status predicted by gender and population covariates.
The variance explained by the score (Vm) was calculated as the difference in
Nagelkerke’s pseudo R2 between the two models. In addition to performing
score analyses for all associated markers, analyses on SNPs within the HLA/
MHC locus only and SNPs not within the HLA/MHC locus (non-HLA) were
also carried out. In these analyses, the model tested included the alternate set as
a covariate, such that for HLA markers we examined (i) case status predicted by
score_HLA, score_non-HLA, gender and population covariates and (ii) case
status predicted by score_non-HLA, gender and population covariates.
The Student’s t-test was used to test for signiﬁcance of the differences in risk
score between groups and we also calculated the Receiver Operator Character-
istic for the scores in the Irish study. All statistical analyses were performed in
STATA v13.
RESULTS
Genetic association
As expected, a highly signiﬁcant association was observed within the
HLA region in our study of 425 Irish coeliac patients and 453
population controls. The frequency of HLA-DQ2.5 carriers (inferred
by rs2187668 chr6:hg18:g.32713862C4T genotype) was 88% in Irish
individuals with celiac disease versus 29% of controls, consistent with
previous ﬁndings.24 The genomic inﬂation factor lambda (λ) was
calculated as 1.12. The strongest association was observed for
rs3891175 which maps to HLA-DQB1 (P= 1.9× 10− 32, OR= 6.22
(95% CI 4.6–8.4)). A summary of the top LD independent ﬁndings is
given in Supplementary Table 1. Outside of the MHC/HLA region, no
additional SNPs achieved GWS (Supplementary Table 2). Manhattan
and QQ plots for SNPs outside of the HLA are shown in Figure 1.
Supplementary Figure 1a shows Manhattan and QQ plots for all SNPs
and Supplementary Figure 1b QQ plots for the null set of SNPs
present on the chip that are not associated with autoimmune diseases.
Replication
Trynka et al14 reported 57 GWS, LD-independent, non-HLA CD
association signals that reached levels of GWS or had been identiﬁed as
such in earlier CD GWAS and replication data sets.11,12 Fifty-six of
these SNPs passed QC in our dataset (imm_21_44453549 was omitted
because of low call rate), and of these, we observed 5 SNPs at Po0.005
and 6 SNPs below or at the nominal association level (Po0.05)
(Table 1). On the basis of the null hypothesis, we would expect to
observe 0 at Po0.005 and less than 3 at Po0.05. This represents
strong evidence for replication and provides additional support for
IL2/IL21 (Pirish o1× 10− 4), SCHIP1, IL12A, PTPN2, SH2B3, ETS1,
TAGAP (Pirish o1× 10− 3), PVT1, DDX6 (Pirish o1× 10− 2) and
RUNX3, RGS1 (Pirish o0.05) as risk loci for CD.
Moreover, by performing a meta-analysis combining the data of
Trynka et al14 and this study, the association signal was strengthened at
several known loci (Supplementary Figure 2), and two additional loci
were identiﬁed which surpassed GWS levels in the combined analysis;
NFIA (rs6691768 chr1:hg18:g.61564451G4A,Pcombined= 2.2 × 10− 8)
and ZNF335 (rs6032606 chr20:hg18:g44029614C4G,Pcombined= 4.81
×10− 8) (Supplementary Table 3).
To test the consistency of the direction of associations with those
previously reported, a binomial sign test was used. There was highly
signiﬁcant evidence of concordance in direction of effect between the
Trynka et al14 and the Irish studies. Of 280 GWS SNPs, 218 (78%)
show effect in the same direction (Pr (K4= 218)= 2.2 × 10− 16).
Figure 1 QQ (left) and Manhattan plot (right) of − log10 (P values) for association for all SNPs on the Immunochip to CD in the Irish sample excluding the
HLA/MHC locus (chr6:20–40Mb).
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Notably, this trend was maintained when analyses were restricted to
the 57 GWS, LD-independent, non-HLA CD association signals,
where 43 of 56 (77%) show the same direction of effect
(Pr (K4= 43)= 5.6× 10− 05) (Supplementary Table 4).
PRS analyses
PRS were calculated at eight association thresholds in our sample
(o5× 10− 8, Po0.01, Po0.05, Po0.1, Po0.2, Po0.3, Po0.4 and
Po0.5). The analysis was applied to three sets of SNPs; all markers,
HLA only and non-HLA. When all markers are included, higher PRS
were found to be signiﬁcantly associated with CD case status at each of
the eight thresholds (Table 2). This was also true when we examined
HLA SNPs only. For the non-HLA SNP set, higher PRS were
signiﬁcantly associated with coeliac case status at the thresholds
Po5× 10− 8, Po0.01, Po0.05 and Po0.1 (see Supplementary
Figures (i)-(xvi)).
Figure 2 shows the proportion of variance explained by PRS at each
of the different thresholds. Up to 35% of the variance was explained
by the PRS when all markers were considered (SNPs threshold
Po0.05; Student’s t test, P= 9.23× 10− 75). Furthermore, up to
4.5% of the variance could be explained by the non-HLA SNPs alone
(SNPs threshold Po0.01; P= 3.6 × 10− 18). Up to 31% of the variance
was explained by the HLA SNPs alone (SNPs threshold Po0.1;
P = 2× 10− 70).
For each threshold, we also estimated the area under the receiver
operating characteristic curve (AUC) (see Supplementary Table 5). For
all markers, the highest AUC was 0.83 (SNPs threshold P o0.05)
(Figure 3a); for non-HLA markers, the AUC was 0.67 (SNPs threshold
Po0.01) (Figure 3b); and for HLA only, the highest AUC was 0.82
(SNPs threshold Po0.5).
DISCUSSION
Recent association studies have added substantially to our under-
standing of the genetic complexity of CD, making it one of the best
understood complex diseases. However, there is still a low probability
of replicating GWS results, so it is important that disease-associated
loci for complex diseases should be replicated in independent
populations.25
In this study, we sought to replicate in an independent Irish
case–control sample, ﬁndings from a recent large Immunochip
analysis carried out by Trynka and colleagues.14 We deﬁned
replicated SNPs as those showing nominally signiﬁcant association
(Po0.05) and a consistent direction of effect. Trynka and
colleagues14 reported 57 independent non-HLA association signals
for CD that had reached GWS, either in their dataset, or earlier
genome-wide studies. We found evidence of replication at 11 of
these SNPs, which was almost four times greater than would be
expected by chance at the Po0.05 level. Genes at these loci include
IL2-IL21, PTPN2, SCHIP1-IL12A, SH2B3, ETS1, TAGAP, PVT1,
TREH-DDX6, RUNX3 and RGS1. Furthermore, there was highly
signiﬁcant evidence of concordance in direction of effect for the
majority (77%) of SNPs that were GWS in the Trynka et al14 study
in our data (both HLA and non-HLA SNPs). This included 12 of
the new loci identiﬁed by Trynka et al14 that had not been
previously implicated in CD, adding further support for these loci
as true coeliac susceptibility loci.
Table 2 The variance explained (R2) for the three sets of SNPs tested (all, HLA only and non-HLA) at the different thresholds tested
Variance explained (delta R2) P values
Threshold (-log10(P)) All non-HLA HLA only All Non-HLA HLA only
5×10−8 0.327 0.041 0.259 1.1×10−69 1.3×10−17 5.6×10−66
0.01 0.343 0.045 0.25 2.0×10−73 3.6×10−18 5.7×10−66
0.05 0.349 0.017 0.294 9.2×10−75 8.3×10−10 3.1×10−71
0.1 0.321 0.005 0.31 1.3×10−58 0.006 2.0×10−70
0.2 0.281 8.9×10−5 0.323 3.8×10−47 0.081 1.5×10−70
0.3 0.266 7.5×10−6 0.328 5.6×10−43 0.128 2.3×10−71
0.4 0.196 2.8×10−5 0.291 6.4×10−26 0.213 2.2×10−62
0.5 0.225 4.0×10−4 0.334 3.7×10−26 0.318 5.3×10−72
P values were calculated for the difference in score between cases and controls using Student’s t test.
Figure 2 Variance explained in an Irish Coeliac cohort by PRS derived from LD-independent SNPs from Trynka et al.14 Red represents the percentage
variance explained (R2) when all markers are analysed (red) and for the non-HLA markers (teal). Shading indicates the proportion of total SNPs included in
the model.
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Increasing the sample size in association studies has been shown to
have more impact in terms of SNP discovery than improving array
coverage even with imputation.26 More risk loci for CD and related
diseases remain to be detected. With even the current large sample
sizes, many true signals of association fall short of the threshold for
GWS. In the largest recent GWAS (of anthropometrics,27 Crohn’s
disease28 and schizophrenia), increases in sample size have yielded a
non-linear increase in the identiﬁed GWS loci. In schizophrenia, for
example, an increase in sample participants from approximately 3000
to 6000 to 9000 and more recently 35 000 resulted in the discovery of
1, 2, 6 and 108 GWS loci, respectively.29
As demonstrated in this study, the modest increase in
sample size brought about by combining the Irish and the
existing Immunochip dataset added sufﬁcient power to raise an
additional two loci beyond the GWS threshold; rs6691768
(PTrynka= 5.3 × 10 − 8; Pcombined= 2.28 × 10 − 8) and rs6032606
(PTrynka= 8.25× 10− 8; Pcombined= 4.81× 10− 8).
rs6691768 is an intronic SNP located in the NFIA gene, which is a
member of the NF1 (nuclear factor 1) family of transcription factors.
It had been identiﬁed by Dubois et al11 as a locus with suggestive
evidence for CD in an earlier GWAS (PDubois combined 1.19× 10
− 7).
NFIA has been most extensively studied in neurological tissue
although there is evidence that it plays an important role in myeloid
lineages.30
rs6032606 is a missense SNP located in the gene ZNF335 which has
not previously been speciﬁcally implicated in CD and is not strongly
associated with other immune mediated diseases, although located in
an extended region identiﬁed as a risk locus for Crohn’s disease,
multiple sclerosis and rheumatoid arthritis (ImmunoBase; www.
immunocase.org). ZNF335 (also known as NIF-1) was originally
shown to modulate nuclear hormone receptor coactivator activity,
thus indirectly affecting the function of a wide variety of nuclear
ligand-bound and other transcription factors including Fos, Jun and
NFkB.31,32 More recently, it has been shown to be a component of the
trithorax chromatin remodelling complex,33 with H3K4 (and perhaps
other31) methyltransferase activity, and its deletion results in embryo-
nic lethality.33 It is a binding partner of another transcriptional
coregulator with chromatin-remodelling activity HCFC131 (HCF1).
HCFC1 is also encoded in a CD susceptibility locus on Xq28.14 Thus,
ZNF335 can profoundly inﬂuence gene expression and in combination
with HCFC1, implicates chromatin remodeling as a molecular
mechanism in CD pathogenesis.
In a PRS analysis using the Trynka and colleagues14 GWAS
summary statistics as a discovery dataset, we examined the collective
inﬂuence of risk alleles on disease susceptibility and assessed the
predictive power of these SNPs present on the Immunochip. Similar
approaches have already been undertaken in CD19,20 but not solely
using the Immunochip. By simultaneously considering variants in
the Immunochip data en masse, we observed strong evidence that
regardless of P-value threshold used, alleles associated with CD from
the earlier studies can explain a signiﬁcant proportion of the variance
in our CD cohort. Increase in the liability is not limited to markers
reaching the standard benchmarks of association, for example, GWS
or Po0.05, but also extends to those with Po0.5, indicating there are
more disease-associated markers to be found amongst these non-
GWS SNPs.
The highest proportion of variance in disease status explained by the
score in our dataset was 35% when all markers are included (Po0.05
threshold) and up to 4.5% excluding the HLA locus (Po0.01). The
latter ﬁnding is in accordance with previous observations in CD and
other complex conditions including schizophrenia15 and multiple
sclerosis,17 in which common non-HLA variants have been found to
explain approximately 3% of the variance in disease risk. In contrast
with other studies, however, the proportion of variance explained
decreased when more liberal discovery thresholds (P40.1) were used
to calculate the polygenic scores, indicating that the signal was being
diluted by the addition of more biologically non-relevant SNPs. The
fact that the Immunochip is not representative of genome-wide
variation but rather a deﬁned subset of loci selected on the basis of
their association with inﬂammatory diseases may also inﬂuence this
observation.
Our ﬁndings are consistent with that of Abraham and colleagues20
who, using a machine learning approach, generated a PRS based on
multiple SNPs that explains 30–35% of disease variance when applied
across several CD cohorts. Their analysis was performed predomi-
nately on datasets genotyped on the Ilumina Inﬁnium array platform
but also included a dataset genotyped on the Immunochip (however,
only SNPs in common to both were included – approximately 4%
overlap). Their data showed a predictive power of 0.86–0.9 (AUC),
which was moderately higher than that reported by Ramonos et al19
who assessed the predictive power of just the 57 non-HLA suscept-
ibility variants combined with HLA genotypes (AUC= 0.854). The
highest AUC in our dataset using SNPs present on the Immunochip
Figure 3 Receiver operator characteristic (ROC) curves and AUCs for the risk
scores at (a) including all markers under the 0.05 threshold and (b) for the
non-HLA markers at the 0.01 threshold.
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was 0.83 (SNPs threshold Po0.05) including the HLA, and 0.67
(SNPs threshold Po0.01) with non-HLA markers only.
It is currently estimated that up to 54% of the heritability of CD can
be explained through a combination of HLA and non-HLA genetic
factors.34 This still leaves a substantial proportion of ‘missing herit-
ability’ to be uncovered, and to date, there is little evidence that rare
variants are contributing substantially to the heritability of CD.35 This
polygene study provides further evidence that common variants are
contributing to the disease. However, PRS are limited in that only
narrow sense heritability (ie a purely additive model of association) is
examined. This method does not take into account the proportion of
variation that is attributable to broad sense heritability, that is, additive,
non-additive, multiplicative and epistatic interactions. Recent studies
have found evidence of epistasis contributing to both psoriasis36 and
multiple sclerosis37 disease risk, indicating that it plays an important
role in risk to other autoimmune diseases but may be difﬁcult to detect
owing to the lack of power or other technical considerations.
One of the biggest advantages of the Immunochip is that it costs a
fraction of standard GWAS chips and is applicable to other immune
diseases. This study shows it has added value as a predictor of CD case
status and it will be instructive to see whether this also applies to other
related diseases. Studies of inﬂammatory bowel disease indicates this to
be likely, where AUCs of 0.86 and 0.83 were predicted for Crohn’s
disease and ulcerative colitis, respectively.38 PRS is a ﬂexible method
that, used in conjunction with low-cost genotyping platforms similar to
the Immunochip, could represent a valuable and cost-efﬁcient tool with
clinical application in assessing the risk of developing these diseases.
Our small sample size is a limitation of this study and meant that
we had insufﬁcient power to observe associations of small effect
(o4% power to detect an association at P o5× 10− 8 (minor allele
frequency 0.5, OR o1.36). Even so, we observe PRS scores that are
sufﬁciently different between cases and controls to predict case status
(AUC 0.83) in line with previous reports.
In conclusion, we have replicated in an independent Irish CD
sample a number of the ﬁndings from a larger Immunochip study
conﬁrming associations at 11 loci. The direction of effect of GWS
signals were highly concordant and our ﬁndings show that the
Immunochip can be used to predict CD case status accurately using
a polygene score method. Finally, by combining our data with earlier
Immunochip studies, we have identiﬁed the regions encoding NFIA
and ZNF335 as GWS CD susceptibility loci.
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